title: Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.
authors.forename: Y
authors.initials: Y
authors.lastname: Jinnouchi
authors.forename: S
authors.initials: S
authors.lastname: Yamagishi
authors.forename: M
authors.initials: M
authors.lastname: Takeuchi
authors.forename: S
authors.initials: S
authors.lastname: Ishida
authors.forename: Y
authors.initials: Y
authors.lastname: Jinnouchi
authors.forename: J
authors.initials: J
authors.lastname: Jinnouchi
authors.forename: T
authors.initials: T
authors.lastname: Imaizumi
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D008297:Male; D016555:Matched-Pair Analysis; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D017127:Glycation End Products, Advanced; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin